Nucleic Acid Amplification Testing (NAAT) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Nucleic Acid Amplification Testing (NAAT) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Nucleic Acid Amplification Testing (NAAT) Market is poised to grow at a CAGR of 8.5% over the forecast period.

The impact of the COVID-19 outbreak on the market growth was substantial as the principal recommendation for the detection of a potent or current SARS-CoV-2 infection was a nucleic acid amplification (NAAT) test that detects one or more specific RNA-specific strains of the virus. According to the study published in Clinical Microbiological Infection in March 2021, titled "Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis" in the COVID-19 diagnostic, the overall NAAT sensitivity was 89.1% and the specificity was 98.9%. The sensitivity of real-time RT-PCR assays was much higher than that of other tests. As a result of the exceptional sensitivity and specificity of NAAT testing in the diagnosis of COVID-19, the demand for such tests spiked amid the pandemic and is likely to continue over the coming years owing to the emergence of multiple strains of the virus.

The major factors for the growth of the nucleic acid amplification testing (NAAT) market include the rising prevalence of infectious diseases; increasing demand for advanced diagnostic measures; and rising investment in the development of new biotechnological diagnostic techniques. There is a high prevalence of infectious diseases such as tuberculosis and HIV, which are further responsible for the increasing demand for diagnostic tests, thereby having a positive impact on the growth of the studied market. For instance, according to the October 2021 report of the World Health Organization, tuberculosis is prevalent in all countries and all age groups, and approximately 10 million people fell ill with tuberculosis (TB) all over the world in 2020, of which eight countries account for two-thirds of the total TB cases in 2020, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Additionally, as per the Global HIV and AIDS Statistics 2021 fact sheet by the Joint United Nations Program on HIV/AIDS (UNAIDS), 37.7 million people worldwide were living with HIV in 2020. Thus, the growing prevalence of infectious diseases is expected to propel the growth of the market.

Rising investments, adoption of key strategies, and product launches are further expected to drive the market in the future. For instance, in January 2021, Xpert Xpress SARS-CoV-2 of Cepheid was launched for the qualitative detection of nucleic acid from the SARS-CoV-2 virus in upper respiratory specimens. Additionally, in December 2021, Roche launched the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni–Utility Channel kit. Cobas HIV-1/HIV-2 Qualitative is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of HIV-1 and HIV-2 in human serum, plasma, and dried blood spots.

Thus, all the aforementioned factors are expected to boost the market's growth over the forecast period. However, a lack of skilled professionals and higher costs associated with these tests may restrain the market's growth.

Key Market TrendsThe Infectious Disease Segment is Expected to Hold the Largest Market Share Over the Forecast Period

Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi. The diseases can spread, directly or indirectly, from one person to another. The common infectious diseases are strep throat and urinary tract infections (caused by bacteria), HIV/AIDS, the common cold (caused by a virus), influenza, STIs, tuberculosis, and athlete's foot (common fungus), among others. For instance, according to the World Health Organization in September 2021, sexually transmitted infections (STIs) have a significant impact on sexual and reproductive health worldwide. Every day, over 1 million STIs are acquired. According to WHO, 374 million new infections with one of four STIs occurred in the year 2020, including chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million). Thus, with the growing prevalence of infectious diseases, the demand for NAAT testing is expected to increase over the forecast period.

Moreover, the recent COVID-19 pandemic has created more development opportunities for different types of diagnostic procedures and technologies for the diagnosis of deadly infections, which may drive market segment growth. Companies and researchers are developing new and advanced POC diagnostic tests for the accurate detection of diseases. For instance, in April 2021, the Indian Institute of Technology of Kharagpur launched its nucleic acid amplification-based point-of-care diagnostic device for COVID-19, "COVIRAP".

Thus, all the aforementioned factors boost the segment's growth over the forecast period.

North America is Expected to Hold a Large Market Share Over the Forecast Period

The North American region is expected to dominate the global market owing to the presence of better healthcare infrastructure, the presence of prominent market players, and the rising prevalence of infectious diseases. According to the estimates of the American Cancer Society, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the United States, and 606,520 people died from the disease. The growing cancer burden is increasing the need for diagnostic tests like NAAT. Additionally, according to the Hepatitis Foundation, in 2021, up to 2.2 million people were chronically infected with Hepatitis B, but only 25% of infected individuals were diagnosed. Therefore, there is an increasing need for better diagnostic tests in the regions, and hence, the major players and the government are focusing on emerging technologies with greater efficacy such as nucleic acid amplification testing.

Additionally, a few of the key market players in the country are developing advanced diagnostics kits to compete with the existing products, while others are acquiring and partnering with the other companies trending in the market. For instance, in March 2022, Thermo Fisher Scientific introduced two novel reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based solutions to support ongoing research and surveillance of viral infections, including SARS-CoV-2. While PCR continues to be the gold standard for diagnostic, lab-based testing, isothermal RT-LAMP nucleic-acid based amplification offers a quick and affordable option for viral infection identification. Such developments are further bolstering the market growth in the region.

Thus, considering all the above-mentioned factors, the market is expected to witness high growth.

Competitive Landscape

The Nucleic Acid Amplification Testing (NAAT) Market studied is moderately fragmented and highly competitive owing to the presence of major market players. Some of the market players are Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc., Grifols SA, Hoffmann-La Roche Ltd., Hologic Inc., and Illumina Inc., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.